AI-driven biomarkers for antibody-drug conjugates
Sherene Loi1, Roberto Salgado2
1Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Cancer Cell
|April 11, 2025
Abstract
None:
Currently, no biomarker reliably predicts the efficacy of antibody-drug conjugates (ADCs). In this issue of Cancer Cell, Ma et al. present a predictive model for HER2-targeting ADC efficacy, incorporating immune-system components, hormone receptor status, clinical staging, and HER2+ cell proportion.
